Wed, Aug 20, 2014, 4:22 PM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Athersys, Inc. Message Board

  • nathang0586 nathang0586 Mar 13, 2013 7:40 AM Flag

    great news

    In our published preclinical studies, the administration of the single dose of MultiStem, even several days after a stroke, resulted in significant and durable recovery.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Based on the positive Phase I data we've summarized previously, we believe MultiStem holds great promise for this area. In the fourth quarter, we submitted our proposed clinical plan to the FDA for their consideration, and it is currently under review. We look forward to hearing their feedback so that we may continue preparations for the next phase of development for this program.We are also collaborating with a leading transplant group at the University of Regensburg in Germany that recently obtained authorization to initiate an institutional sponsored clinical trial, exploring the administration of MultiStem in patients following a liver transplant. We will provide limited financial support for this investigator sponsored Phase I study and provide clinical grade product to conduct a trial.

      Sentiment: Strong Buy

1.500.00(0.00%)4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.